Idevax SRL
4.9 FTEIdevax reported total assets of €3.95m at the end of the 2025 financial year (annual accounts filed with the NBB on 26 May 2026), with 4.9 full-time equivalents.
The score of Idevax shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +591 % Total assets +451 % Headcount (avg FTE) +250 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Idevax's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 26 May 2026
- Year ended 31 Dec 2024filed on 22 Jul 2025
- Year ended 31 Dec 2023filed on 15 Oct 2024
- Year ended 31 Dec 2022filed on 28 Sep 2023
- Year ended 31 Dec 2021filed on 25 Aug 2022
Idevax's financial analysis
- Solvency58.1%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Idevax
Idevax's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0759.573.445
- VAT number
- BE0759573445
- Peppol
- Registered · 0208:0759573445 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 08 Dec 2020
- Registered office
- 2110 Wijnegem
- Size
- Micro · 4.9 FTE
- Latest accounts
- 2025 · filed on 26 May 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Idevax (SRL) has been based in Wijnegem since 2020, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 607,429 € and equity of €2.29m; its revenue is not published. With 4.9 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 58.1%, above the median of its sector (56.0%).
Companies similar to Idevax
Companies in the same business, of comparable size and area, outside its group.
- MeiraGTx Belgium Manufacture of basic pharmaceutical products Ghent · balance sheet €4.44m
- Pharma Chemicals Manufacture of pharmaceutical preparations Braine-le-Château · balance sheet €3.25m
- Prevor Manufacture of basic pharmaceutical products Liège · balance sheet €3.75m
- Spark CRC Manufacture of basic pharmaceutical products Waasmunster · balance sheet €3.11m
- Diagam Manufacture of basic pharmaceutical products Ath · balance sheet €7.25m
- Elysia Wholesale of pharmaceutical and medical goods Seraing · balance sheet €8.00m
- ExoXpert Manufacture of pharmaceutical preparations Liège · balance sheet €2.05m
- Sartorius Xpress Biologics Manufacture of basic pharmaceutical products Herstal · balance sheet €10.9m
Frequently asked questions about Idevax
What is the revenue of Idevax?
Idevax files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Idevax?
In Belgium, the VAT number is the company number prefixed with BE: BE0759573445 for Idevax, if the company is VAT-registered. Its company number (CBE) is 0759.573.445.
Where is the registered office of Idevax?
According to the CBE register, the registered office of Idevax is in 2110 Wijnegem.
What is the equity of Idevax?
At the close of the 2025 financial year, the equity of Idevax amounts to 2,294,859 €, a solvency of 58.1% of total assets.
How many people work at Idevax?
4.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Idevax?
The register lists 8 active mandates at Idevax. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Idevax
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →